Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;27(9):761-70.
doi: 10.1177/0269881113495118. Epub 2013 Jul 24.

The size, burden and cost of disorders of the brain in the UK

Naomi A Fineberg  1 , Peter M Haddad, Lewis Carpenter, Brenda Gannon, Rachel Sharpe, Allan H Young, Eileen Joyce, James Rowe, David Wellsted, David J Nutt, Barbara J Sahakian
Affiliations

The size, burden and cost of disorders of the brain in the UK

Naomi A Fineberg et al. J Psychopharmacol. 2013 Sep.

Abstract

Aim: The aim of this paper is to increase awareness of the prevalence and cost of psychiatric and neurological disorders (brain disorders) in the UK.

Method: UK data for 18 brain disorders were extracted from a systematic review of European epidemiological data and prevalence rates and the costs of each disorder were summarized (2010 values).

Results: There were approximately 45 million cases of brain disorders in the UK, with a cost of €134 billion per annum. The most prevalent were headache, anxiety disorders, sleep disorders, mood disorders and somatoform disorders. However, the five most costly disorders (€ million) were: dementia: €22,164; psychotic disorders: €16,717; mood disorders: €19,238; addiction: €11,719; anxiety disorders: €11,687. Apart from psychosis, these five disorders ranked amongst those with the lowest direct medical expenditure per subject (<€3000). The approximate breakdown of costs was: 50% indirect costs, 25% direct non-medical and 25% direct healthcare costs.

Discussion: The prevalence and cost of UK brain disorders is likely to increase given the ageing population. Translational neurosciences research has the potential to develop more effective treatments but is underfunded. Addressing the clinical and economic challenges posed by brain disorders requires a coordinated effort at an EU and national level to transform the current scientific, healthcare and educational agenda.

Keywords: Brain disorders; burden; cost.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The following relate to activity within the past five years.

Consultancy

Dr Fineberg has consulted for Lundbeck, Glaxo-Smith Kline, Transcept, Novartis and Servier.

Research support

Dr Fineberg has received research support from Lundbeck, Glaxo-SmithKline, Wellcome, Cephalon, European College of Neuropsychopharmacology (ECNP), Servier, UK Medical Research Council, UK National Institute of Health Research.

Honoraria for lectures

Dr Fineberg has received honoraria for lectures at scientific meetings from Janssen, Lundbeck, Servier, Astra Zeneca, Wyeth, Bristol Myers Squibb.

Financial support to attend scientific meetings

Dr Fineberg has received financial support to attend scientific meetings from Lundbeck, Servier, Bristol Myers Squibb, International College of Obsessive Compulsive Spectrum Disorders, British Association for Psychopharmacology, International Conference on Behavioral Addictions, ECNP, World Health Organization.

Peter Haddad

In the last 3 years PMH has received support to attend conferences and/or fees for lecturing and consultancy work (including attending advisory boards) from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Otsuka, Servier and Sunovion.

Barbara Sahakian

Barbara Sahakian consults for Cambridge Cognition, Servier and Lundbeck. She holds a grant from Janssen/J&J.

David Nutt

In the last 2 years I have consulted for Lundbeck, Pfizer, GSK, Rekitts, BMS, Lilly and Otsuka.

Figures

Figure 1.
Figure 1.
Estimated 12-month UK prevalence of disorders of the brain.
Figure 2.
Figure 2.
UK per-subject cost of brain disorders.
Figure 3.
Figure 3.
Total UK cost of individual brain disorders.
See this image and copyright information in PMC

References

    1. AccessEconomics (2007) The cost of muscular dystrophy. Muscular Dystrophy Association. AccessEconomics.
    1. Alzheimer’s Society (2007) A report to the Alzheimer’s Society on the prevalence and economic cost of dementia in the UK produced by King’s College London and London School of Economics. London: Dementia UK.
    1. Andlin-Sobocki P, Bengt Jönsson P, Wittchen HU. (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12: 1–27. - PubMed
    1. APA (American Psychiatric Association) (1980) Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: American Psychiatric Association.
    1. APA (American Psychiatric Association) (1987) Diagnostic and statistical manual of mental disorders (3rd ed., revised). Washington, DC: American Psychiatric Association.

Publication types